Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years

被引：0
|
作者：
Lisi M. Dredze
Michael Friger
Samuel Ariad
Michael Koretz
Bertha Delgado
Ruthy Shaco-Levy
Margarita Tokar
Michael Bayme
Ravit Agassi
Maia Rosenthal
Victor Dyomin
Olga Belochitski
Shai Libson
Tamar Mizrahi
David B. Geffen
机构：
[1] Ben-Gurion University of the Negev,Faculty of Health Sciences
[2] Soroka University Medical Center,Department of Oncology
[3] Ben-Gurion University of the Negev,Department of Public Health
[4] Soroka Medical Center,Division of Surgery and The Eshkol Breast Center
[5] Soroka University Medical Center,Department of Pathology
[6] Soroka Medical Center,Department of Imaging and The Eshkol Breast Center
来源：
Breast Cancer Research and Treatment | 2022年 / 193卷
关键词：
Neoadjuvant; Doxorubicin-cyclophosphamide; Paclitaxel; Breast cancer; Real-world;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：597 / 612
页数：15
相关论文
共 45 条
  • [1] Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years
    Dredze, Lisi M.
    Friger, Michael
    Ariad, Samuel
    Koretz, Michael
    Delgado, Bertha
    Shaco-Levy, Ruthy
    Tokar, Margarita
    Bayme, Michael
    Agassi, Ravit
    Rosenthal, Maia
    Dyomin, Victor
    Belochitski, Olga
    Libson, Shai
    Mizrahi, Tamar
    Geffen, David B.
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 193 (03) : 597 - 612
  • [2] Neoadjuvant doxorubicin/cyclophosphamide followed by weekly paclitaxel for operable or locally advanced breast cancer: outcome analysis of 72 patients treated at a single institution
    Tokar, M.
    Koretz, M.
    Hertz, T.
    Bloshitski, O.
    Delgado, B.
    Sion-Vardy, N.
    Ariad, S.
    Bayme, M.
    Geffen, D. B.
    EJC SUPPLEMENTS, 2010, 8 (03): : 75 - 75
  • [3] Neoadjuvant Doxorubicin-Paclitaxel Combined Chemotherapy in Patients with Inoperable Stage III Breast Cancer: A Retrospective Cohort Study with 10 Years of Follow-Up in Vietnam
    Le, Duc Thanh
    Bui, Lap Thanh
    Nguyen, Chu Van
    Do, Kien Hung
    Tran, Giang Le
    Do, Tu Anh
    ONCOLOGY AND THERAPY, 2023, 11 (03) : 327 - 341
  • [4] Neoadjuvant Doxorubicin-Paclitaxel Combined Chemotherapy in Patients with Inoperable Stage III Breast Cancer: A Retrospective Cohort Study with 10 Years of Follow-Up in Vietnam
    Duc Thanh Le
    Lap Thanh Bui
    Chu Van Nguyen
    Kien Hung Do
    Giang Le Tran
    Tu Anh Do
    Oncology and Therapy, 2023, 11 : 327 - 341
  • [5] Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience
    Singh, Jasmeet C.
    Mamtani, Anita
    Barrio, Andrea
    Morrow, Monica
    Sugarman, Steven
    Jones, Lee W.
    Yu, Anthony F.
    Argolo, Daniel
    Smyth, Lilian M.
    Modi, Shanu
    Schweber, Sarah
    Boafo, Camilla
    Patil, Sujata
    Norton, Larry
    Baselga, Jose
    Hudis, Clifford A.
    Dang, Chau
    ONCOLOGIST, 2017, 22 (02): : 139 - 143
  • [6] Sentinel node biopsy for axillary management after neoadjuvant therapy for breast cancer: a single-center retrospective analysis with long follow-up
    Ogawa, Yoshinari
    Ikeda, Katsumi
    Watanabe, Chika
    Kamei, Yuri
    Tokunaga, Shinya
    Tsuboguchi, Yuko
    Inoue, Takeshi
    Fukushima, Hiroko
    Ichiki, Makoto
    SURGERY TODAY, 2018, 48 (01) : 87 - 94
  • [7] Sentinel node biopsy for axillary management after neoadjuvant therapy for breast cancer: a single-center retrospective analysis with long follow-up
    Yoshinari Ogawa
    Katsumi Ikeda
    Chika Watanabe
    Yuri Kamei
    Shinya Tokunaga
    Yuko Tsuboguchi
    Takeshi Inoue
    Hiroko Fukushima
    Makoto Ichiki
    Surgery Today, 2018, 48 : 87 - 94
  • [8] 7 years follow-up among patients with early stage breast cancer treated with single fraction IORT
    Horst, K.
    Dirbas, F.
    Fasola, C.
    Goffinet, D.
    Daniel, B.
    Ikeda, D.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S236 - S236
  • [9] A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy (NACT) for early breast cancer: Three-year follow-up data
    Schneeweiss, Andreas
    Ruiz, Amparo
    Manikhas, Alexey
    Bottini, Alberto
    Rovira, Pedro Sanchez
    Mansouri, Kambiz
    Kazeem, Gbenga
    Bauknecht, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis
    Cocciolone, Valentina
    Cannita, Katia
    Calandrella, Maria Letizia
    Ricevuto, Enrico
    Baldi, Paola Lanfiuti
    Sidoni, Tina
    Irelli, Azzurra
    Paradisi, Stefania
    Pizzorno, Laura
    Resta, Valter
    Bafile, Alberto
    Alesse, Edoardo
    Tessitore, Alessandra
    Ficorella, Corrado
    ONCOTARGET, 2017, 8 (42) : 72031 - 72043
12345